[ad_1]
Charter lost fewer internet subscribers than expected in the second quarter, though subscriber losses in its video business were steeper than what analysts were modeling.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...